Canaccord raised the firm’s price target on Mind Medicine (MNMD) to $25 from $16 and keeps a Buy rating on the shares. The firm added its MDD drug potential to its model and said the company is well capitalized and significantly undervalued heading into Phase 3 data.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MNMD:
- Mind Medicine’s Accelerated Phase 3 Trials and Strong Financial Position Signal Promising Future
- MindMed Reports Q3 2025 Financial Progress
- Mind Medicine Reports Q3 2025 Financial Results
- Mind Medicine reports Q3 EPS (78c), consensus (50c)
- MindMed Secures $259 Million in Public Offering to Advance Brain Health Innovations